Moderna CMO Jacqueline Miller to step down

Reuters01-30 22:01

<a href="https://laohu8.com/S/MRNA">Moderna</a> CMO Jacqueline Miller to step down

Jan 30 (Reuters) - Moderna's MRNA.O Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.

Miller joined Moderna in 2020 as the therapeutic area head for infectious diseases. Her departure comes at a pivotal moment for the company, which is seeking to plug the revenue gap left by waning demand for COVID products and turn its mRNA platform into a broader, durable franchise.

Over her career, Miller has supported seven novel vaccine approvals for patients ranging from infants to older adults, including Moderna's Spikevax and respiratory syncytial virus vaccine mRESVIA, according to the company's website.

Shares of Moderna were down over 2% in premarket trading.

The company named David Berman as Chief Development Officer beginning from March 2. Miller will remain as a consultant to the company to assist with the transition, it added.

Before joining Moderna, Berman served as head of research and development at Immunocore IMCR.O and has previously held senior roles at AstraZeneca AZN.L and Bristol-Myers Squibb BMY.N.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607793046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607793046","market":"us","top_or_hot":-1,"title":"Moderna CMO Jacqueline Miller to step down","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/MRNA\">Moderna</a> CMO Jacqueline Miller to step down   </title></head><body><p><span>Jan 30 (Reuters)</span><span> - </span>Moderna's <span>MRNA.O</span> Chief Medical Officer Jacqueline Miller, <span>who led the development of the company's mRNA-based COVID-19 vaccine Spikevax</span>, will step down effective March 2, the vaccine maker said on Friday.  </p><p>Miller joined Moderna in 2020 as the therapeutic area head for infectious diseases. Her departure comes at a pivotal moment for the company, which is seeking to plug the revenue gap left by waning demand for COVID products and turn its mRNA platform into a broader, durable franchise.</p><p>Over her career, Miller has supported seven novel vaccine approvals for patients ranging from infants to older adults, including Moderna's Spikevax and respiratory syncytial virus vaccine mRESVIA, according to the company's website.</p><p>Shares of Moderna were down over 2% in premarket trading.</p><p>The company named David Berman as Chief Development Officer beginning from March 2. Miller will remain as a consultant to the company to assist with the transition, it added.    </p><p>Before joining Moderna, Berman served as head of research and development at Immunocore <span>IMCR.O</span> and has previously held senior roles at AstraZeneca <span>AZN.L</span> and <a href=\"https://laohu8.com/S/BMYMP\">Bristol-Myers Squibb</a> <span>BMY.N</span>.             </p><p> (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)</p><p> ((Mariam.ESunny@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CMO Jacqueline Miller to step down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CMO Jacqueline Miller to step down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-30 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/MRNA\">Moderna</a> CMO Jacqueline Miller to step down   </title></head><body><p><span>Jan 30 (Reuters)</span><span> - </span>Moderna's <span>MRNA.O</span> Chief Medical Officer Jacqueline Miller, <span>who led the development of the company's mRNA-based COVID-19 vaccine Spikevax</span>, will step down effective March 2, the vaccine maker said on Friday.  </p><p>Miller joined Moderna in 2020 as the therapeutic area head for infectious diseases. Her departure comes at a pivotal moment for the company, which is seeking to plug the revenue gap left by waning demand for COVID products and turn its mRNA platform into a broader, durable franchise.</p><p>Over her career, Miller has supported seven novel vaccine approvals for patients ranging from infants to older adults, including Moderna's Spikevax and respiratory syncytial virus vaccine mRESVIA, according to the company's website.</p><p>Shares of Moderna were down over 2% in premarket trading.</p><p>The company named David Berman as Chief Development Officer beginning from March 2. Miller will remain as a consultant to the company to assist with the transition, it added.    </p><p>Before joining Moderna, Berman served as head of research and development at Immunocore <span>IMCR.O</span> and has previously held senior roles at AstraZeneca <span>AZN.L</span> and <a href=\"https://laohu8.com/S/BMYMP\">Bristol-Myers Squibb</a> <span>BMY.N</span>.             </p><p> (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)</p><p> ((Mariam.ESunny@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0432979614.USD","symbol_name":"JPM GLOBAL HEALTHCARE \"A\" ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nL4N3YV1GH:1","article_id":"2607793046","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607793046","pubTimestamp":1769781665,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Moderna CMO Jacqueline Miller to step down   Jan 30  - Moderna's MRNA.O Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.  Miller joined Moderna in 2020 as the therapeutic area head for infectious diseases. Her departure comes at a pivotal moment for the company, which is seeking to plug the revenue gap left by waning demand for COVID products and turn its mRNA platform into a broader, durable franchise.Over her career, Miller has supported seven novel vaccine approvals for patients ranging from infants to older adults, including Moderna's Spikevax and respiratory syncytial virus vaccine mRESVIA, according to the company's website.Shares of Moderna were down over 2% in premarket trading.The company named David Berman as Chief Development Officer beginning from March 2. Miller will remain as a consultant to the company to assist with the transition, i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1301847155.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A4G\" (USD) INC","LU1078025761.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","03165":"华夏欧优股对冲","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","AZN.UK":"阿斯利康制药","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0827474353.SGD":"Allianz Europe Equity Growth Cl AT Acc H2-SGD","MRNA":"Moderna, Inc.","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1880407132.USD":"AMUNDI FUNDS NET ZERO AMBITION TOP EUROPEAN PLAYERS \"A2\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0857590862.USD":"ALLIANZ EUROPE EQUITY GROWTH \"AT\" (USDHDG) H2 ACC","LU0972486137.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AUH\" (USDHDG) ACC","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC","LU1487256676.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ZUH\" (USDHDG) ACC","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H","LU2539964713.USD":"SCHRODER ISF EUROPEAN SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0964806797.USD":"UBS (LUX) EQUITY FUND - EUROPEAN OPPORTUNITY SUSTAINABLE (EUR) \"P\" (USHDG) ACC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","BMY":"施贵宝","IMCR":"Immunocore Holdings plc","LU1880407215.USD":"AMUNDI FUNDS NET ZERO AMBITION TOP EUROPEAN PLAYERS \"A2\" (USD) INC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4007":"制药","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU0920783379.SGD":"Allianz Europe Equity Growth Select Cl AT Acc H2-SGD"},"translate_title":"Moderna CMO杰奎琳·米勒辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9,"03165":0.6,"AZN.UK":0.9,"MRNA":0.9,"IMCR":0.9},"content_text":"Moderna CMO Jacqueline Miller to step down   Jan 30 (Reuters) - Moderna's MRNA.O Chief Medical Officer Jacqueline Miller, who led the development of the company's mRNA-based COVID-19 vaccine Spikevax, will step down effective March 2, the vaccine maker said on Friday.  Miller joined Moderna in 2020 as the therapeutic area head for infectious diseases. Her departure comes at a pivotal moment for the company, which is seeking to plug the revenue gap left by waning demand for COVID products and turn its mRNA platform into a broader, durable franchise.Over her career, Miller has supported seven novel vaccine approvals for patients ranging from infants to older adults, including Moderna's Spikevax and respiratory syncytial virus vaccine mRESVIA, according to the company's website.Shares of Moderna were down over 2% in premarket trading.The company named David Berman as Chief Development Officer beginning from March 2. Miller will remain as a consultant to the company to assist with the transition, it added.    Before joining Moderna, Berman served as head of research and development at Immunocore IMCR.O and has previously held senior roles at AstraZeneca AZN.L and Bristol-Myers Squibb BMY.N.              (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber) ((Mariam.ESunny@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607793046","isCrawlerRequest":true}